On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Hold from Buy at Investec. 2. Charles Schwab (SCHW) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying while Schwab's business is growing more rapidly than traditional asset managers, there also seems to be "multiple compression on market sensitive revenues given risks to that outlook." 3. Pan American Silver (PAAS) downgraded to Underperform from Neutral at BofA/Merrill with analyst Lawson Winder citing substantial risk assumed from the Tahoe Resources (TAHO) acquisition and the high priced paid. 4. PNC Financial (PNC) downgraded to Market Perform from Outperform at BMO Capital with analyst Lana Chan saying that the stock is approaching her prior $139 per share forecast and sees the company as challenged in gaining market share through expansion given the competition from other Universal banks. 5. Madrigal Pharmaceuticals (MDGL) downgraded to Underperform at Raymond James with analyst Steven Seedhouse saying he expected MGL-3196 Phase 2 data sentiment to worsen exiting AASLD, but that it was exacerbated by the NASH resolution definition informing the seemingly large effect size of 27% versus 6% was not what he expected. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.